What's New
by Year
2016
Dec. 26, 2016 Corporate
Posted Conference Call for Acquisition of Tolero Pharmaceuticals, Inc. [Webcast]
Dec. 26, 2016 (PDF/112KB) Licensing
Sumitomo Dainippon Pharma to Conduct Meropenem Business in Five Countries of South-East Asia and Hong Kong
Dec. 22, 2016 (PDF/153KB) Licensing
Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Dec. 21, 2016 (PDF/686KB) Corporate
Teleconference Material (Acquisition of Tolero Pharmaceuticals, Inc.)
Dec. 21, 2016 (PDF/153KB) Corporate
Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Dec. 21, 2016 (PDF/98KB) Corporate
Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
Dec. 01, 2016 Others
Posted Factbook 2016 ver.2
Nov. 11, 2016 (PDF/119KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Nov. 04, 2016 (PDF/95KB) R&D
Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016
Nov. 02, 2016 Finances
Posted Video of Second Quarter Financial Results for FY2016 [Webcast]
Oct. 27, 2016 (PDF/1,120KB) Finances
Presentation Material (Second Quarter Financial Results for FY2016)
Oct. 27, 2016 (PDF/562KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2017
Oct. 27, 2016 (PDF/297KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
Oct. 27, 2016 (PDF/77KB) Corporate
Sumitomo Dainippon Pharma Announces the Establishment of a Subsidiary for Promotion of Authorized Generics and others
Oct. 24, 2016 (PDF/84KB) Corporate
Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Oct. 21, 2016 (PDF/239KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ended September 30, 2016
Oct. 21, 2016 (PDF/112KB) Corporate
Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
Oct. 13, 2016 (PDF/322KB) R&D
Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Oct. 06, 2016 (PDF/146KB) R&D
Sumitomo Dainippon Pharma announces the final data analysis of a global phase 3 study of an investigational anti-cancer drug Napabucasin (CO.23 study) will be presented at the ESMO 2016 Congress
Sep. 29, 2016 Others
Posted Annual Report 2016
Sep. 20, 2016 (PDF/188KB) R&D
Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Sep. 01, 2016 (PDF/102KB) Corporate
Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion to Acquire Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Aug. 30, 2016 (PDF/132KB) Corporate
Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees and Reduction in Executive Remuneration
Jul. 29, 2016 (PDF/316KB) R&D
Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Jul. 29, 2016 Finances
Posted Conference Call for First Quarter Financial Results for FY2016 [Webcast]
Jul. 27, 2016 (PDF/844KB) Finances
Presentation Material (First Quarter Financial Results for FY2016)
Jul. 27, 2016 (PDF/537KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2017
Jul. 27, 2016 (PDF/283KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
Jul. 26, 2016 (PDF/76KB) R&D
Sysmex, Healios and Sumitomo Dainippon Pharma Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells
Jul. 25, 2016 (PDF/131KB) CSR
Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment for the 14th Consecutive Year
Jun. 24, 2016 Others
Posted FactBook 2016
Jun. 07, 2016 R&D
Posted the posters regarding napabucasin（BBI608） and amcasertib（BBI503） were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on the website of Boston Biomedical
May 31, 2016 Others
Posted Notice of Convocation of the 196th Annual Shareholders’ Meeting
May 19, 2016 (PDF/58KB) R&D
Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drugs Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016
May 18, 2016 Finances
Posted Video of Financial Results for FY2015 [Webcast]
May 11, 2016 (PDF/1,176KB) Finances
Presentation Material (Financial Results for FY2015)
May 11, 2016 (PDF/548KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2016
May 11, 2016 (PDF/969KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2016 [Japanese GAAP] (Unaudited)
May 11, 2016 (PDF/115KB) Corporate
Sumitomo Dainippon Pharma announces Change of Directors
Apr. 27, 2016 (PDF/316KB) R&D
Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Apr. 19, 2016 (PDF/44KB) CSR
Sumitomo Dainippon Pharma Contributes to Kumamoto Earthquake Relief Efforts in Japan
Apr. 11, 2016 (PDF/115KB) R&D
Kyoto University and Sumitomo Dainippon Pharma Launch Second Stage of Joint Research Project for Innovative Oncology Therapeutics (DSK Project)
Mar. 01, 2016 (PDF/103KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Jan. 29, 2016 Finances
Posted Conference Call for Third Quarter Financial Results for FY2015 [Webcast]
Jan. 27, 2016 (PDF/1,385KB) Finances
Presentation Material (Third Quarter Financial Results for FY2015)
Jan. 27, 2016 (PDF/549KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2016
Jan. 27, 2016 (PDF/330KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
Jan. 25, 2016 (PDF/57KB) R&D
Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Jan. 25, 2016 (PDF/229KB) R&D
Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline